Melan-A -ELA + NY-ESO-1b + MAGE-A10 + Montanide + CpG

This is a multi-peptide cancer vaccine formulation designed for immunotherapy in melanoma and other cancers expressing the relevant tumor antigens. The vaccine contains synthetic peptides derived from three tumor-associated antigens—Melan-A (also known as MART-1, specifically the ELA analog), NY-ESO-1b, and MAGE-A10—combined with two adjuvants: Montanide ISA 51 (a water-in-oil emulsion used to enhance immune response) and CpG oligodeoxynucleotides (TLR9 agonists that stimulate innate immunity). The mechanism of action involves induction of antigen-specific CD8+ T-cell responses against tumor cells expressing these antigens, aiming to promote anti-tumor immunity. This combination has been studied primarily in patients with advanced melanoma[1][2][4].

Other names

Melanoma Antigen Peptide VaccineCHUV Melanoma VaccineMelan-A/Mart-1 Analog (ELA), NY-ESO-1b(A) Analog and MAGE-A10 Vaccine